Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Subjects With Advanced Solid Tumours Likely to Over-Express the Epidermal Growth Factor Receptor (EGFR)

Next Previous
Trial Profile

A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Subjects With Advanced Solid Tumours Likely to Over-Express the Epidermal Growth Factor Receptor (EGFR)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Depatuxizumab mafodotin (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors AbbVie

Most Recent Events

  • 13 Mar 2018 According to results published in the Cancer, study was designed as a phase 1 and 2 however, the study sponsor ultimately decided not to extend the study into the phase 2 expansion cohort, and no patients were enrolled in that phase.
  • 13 Mar 2018 Results assessing the safety, pharmacokinetics, and efficacy of depatux-m in patients who had advanced solid tumors, were published in the Cancer.
  • 07 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top